【摘要】 目的总结归纳术前新辅助化疗对ⅢA期非小细胞肺癌(NSCLC)的近-中期临床疗效。方法2010年8月~2016年8月,102例肺癌患者接受手术治疗,术后病理诊断为ⅢA期NSCLC;其中33例(观察组)患者术前接受2周期的新辅助化疗、并于化疗结束后3~4周行常规肺癌根治手术;69例(对照组)未行术前化疗而直接手术。对两组患者临床资料及术后随访资料进行回顾性分析。结果观察组术前新辅助化疗有效率为63.6%,均经胸腔镜或常规开胸完成肺癌根治术,无手术死亡;对照组因术后感染手术死亡2例;两组患者手术切除率无显著差异;术后随访3年内无失访,观察组3年生存率高于对照组。结论新辅助化疗不增加手术难度,并有望延长生存期,改善生活治疗,值得进一步临床推广应用。更多还原

【Abstract】 Objective To summarize the clinical effects of neoadjuvant chemotherapy in patients with stage IIIA non-small cell lung cancer(NSCLC).Methods From August 2010 to August 2016,there were 102 patients underwent surgery for lung cancer,and the postoperative pathological diagnoses were confirmed as stage IIIA NSCLC.Among them,33 cases received 2 cycles of neoadjuvant chemotherapy before the radical surgery for lung cancer 3-4 weeks late(observation group),and 69 cases(control group) underwent surgery for lung cancer without preoperative chemotherapy.The clinical data as well as early and meddle term surgical outcome of both groups were analyzed retrospectively.Results The neoadjuvant chemotherapy effective rate was 63.6% in the observation group.All surgeries for lung cancer patients were undertaken either with video-assisted thoracotomy or traditional thoracotomy.There were 2 death cases in the control group.The resection rate was similar between the observation group and the control group.All patients were followed up at least 3 years,and the 3 years survival rate of the observation group was higher than that of the control group.Conclusion Preoperative neoadjuvant chemotherapy in patients with NSCLC will not compromise the resection rate and prolong the survival time,which is worthy of clinical application.更多还原